Of the ten advanced therapy medicinal products to have been approved in Europe, three – Strimvelis, Zalmoxis and Holoclar – have been developed in Italy, which is rapidly asserting itself as a leading player in the field of cell and gene therapies.
Strimvelis was developed at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Milan, and received marketing authorisation for the treatment of ADA-SCID, a severe and very rare form of immunodeficiency, in May 2016. The first ex vivo gene therapy to be approved in the world, it was brought to market under a strategic alliance with pharmaceutical giant GlaxoSmithKline. In April 2018, GlaxoSmithKline signed a strategic agreement to transfer its rare disease gene therapy portfolio (including Strimvelis) to Orchard Therapeutics.
SOURCE: https://www.healtheuropa.eu
Dennis Palumbo is a thriller writer and psychotherapist in private practice. He's the auth...
Arnaldo Trabucco, MD, FACS is a leading urologist who received his medical training at ins...
You can tell she fills with excitement when she has the chance to show an important archae...
In mattinata ha incontrato il sindaco di Como, Mario Lucini, assieme all'assessore Gisella...
AGENDA 12.00 – 12.15 Light lunch12.15 – 12.30Welcome addresses Lorenzo Mannelli, MD, PhD...
by Claudia Astarita The food farming sector is still one of the engines of Italia...
by Claudia Astarita A recent study on 120 artisan SMEs of excellence – conducted...
Sunday, November 23 - 2 pmWhen: Sunday, November 23, 2014 2:00-4:00 pm Where: UL 1126 in t...